首页> 外文期刊>Molecular medicine reports >Biological characteristics of the A1762T/G1764A mutant strain of hepatitis B virus in vivo
【24h】

Biological characteristics of the A1762T/G1764A mutant strain of hepatitis B virus in vivo

机译:乙型肝炎病毒A1762T / G1764A突变株的体内生物学特性

获取原文
获取原文并翻译 | 示例
       

摘要

The double nucleotide, A1762T and G1764A exchange (TA mutation), in the hepatitis B virus (HBV) genome basal core promoter (BCP) region is a common viral mutation in patients with chronic HBV infection. This mutation is located in the binding site of hepatocyte nuclear factor 4 (HNF4), and a number of liver-enriched transcription factors are involved in the regulation of HBV transcription and replication. The aim of the present study was to investigate the biological characteristics of the HBV strain with this mutation, and the effect of HNF4 inhibition on the replication of this strain in vivo. The results indicated that in vivo the HBV strain with the TA mutation supported a higher level of pregenomic RNA transcription and HBV DNA replication, compared with the wild-type strain. Furthermore, the concentration of serum HBeAg in the TA mutant group was lower than that in the wild-type strain. Following treatment of the mice with entecavir (ETV) or tenofovir disoproxil fumarate (TDF), the transcription and replication levels of wild-type and mutant strains were reduced. In the groups treated with TDF, the inhibition effect was more marked. In hepatocytes in which HNF4 expression was specifically inhibited, the level of 3.5 kb mRNA of HBV was reduced compared with that in mouse cells with normal HNF4 expression, and HBV DNA replication levels were also reduced to a greater extent. Furthermore, following liver-specific knockdown of HNF4, the reduction in variant virus expression was greater than that of the wild-type virus. In conclusion, the replication capacity of HBV with the TA mutation was increased, and the mutation was associated with a reduction in serum HBeAg levels. This mutant strain remained sensitive to ETV and TDF, and HNF4 supported a higher replication level of TA mutant HBV in vivo.
机译:乙型肝炎病毒(HBV)基因组基础核心启动子(BCP)区中的双核苷酸A1762T和G1764A交换(TA突变)是慢性HBV感染患者的常见病毒突变。该突变位于肝细胞核因子4(HNF4)的结合位点,许多肝脏富集的转录因子参与了HBV转录和复制的调控。本研究的目的是研究具有此突变的HBV菌株的生物学特性,以及HNF4抑制对其在体内复制的影响。结果表明,与野生型菌株相比,体内具有TA突变的HBV菌株支持更高水平的基因组RNA转录和HBV DNA复制。此外,TA突变体组的血清HBeAg浓度低于野生型菌株。用恩替卡韦(ETV)或替诺福韦富马酸替诺福韦酯(TDF)处理小鼠后,野生型和突变株的转录和复制水平降低。在用TDF处理的组中,抑制作用更加明显。与正常表达HNF4的小鼠细胞相比,在特异性抑制HNF4表达的肝细胞中HBV的3.5 kb mRNA水平降低,并且HBV DNA复制水平也更大程度地降低。此外,在肝特异性敲除HNF4之后,变异病毒表达的降低大于野生型病毒的降低。总之,带有TA突变的HBV的复制能力增加,并且该突变与血清HBeAg水平降低有关。该突变株仍然对ETV和TDF敏感,并且HNF4支持TA突变株HBV在体内更高的复制水平。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号